1 / 21

A Generic Medicines Sector View on Sustainable Development in Pharmaceuticals

A Generic Medicines Sector View on Sustainable Development in Pharmaceuticals. Uppsala, 10 Nov 2009 Sean Bowler VP Engineering and EHS, Actavis. Contents. The European Generic medicines Association & Generic Medicines Medicinal Product Life Cycle Specific Challenges for the Generic Sector

johnsrivera
Download Presentation

A Generic Medicines Sector View on Sustainable Development in Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Generic Medicines Sector View on Sustainable Development in Pharmaceuticals Uppsala, 10 Nov 2009 Sean Bowler VP Engineering and EHS, Actavis

  2. Contents • The European Generic medicines Association & Generic Medicines • Medicinal Product Life Cycle • Specific Challenges for the Generic Sector • Actavis – How one company manages EHS • Way forward

  3. The European Generic medicines Association (EGA)

  4. The EGA & Generic Medicines • EGA represents over 700 companies in 34 European countries • Generic medicines companies employ over 130,000 people in the EU • Generic medicines account for nearly 50% of packs dispensed in the EU and 18% of pharmaceutical expenditure 5

  5. Generic Medicines- Key Healthcare Provider • Committed to Healthcare and Improvement of Life & Health Quality • Mature and responsible pharmaceutical sector • Ensuring access to high-quality affordable medicines 6

  6. Medicinal PRODUCT LIFE CYCLE

  7. Traditional Product Life Cycle 8

  8. Product Life Cycle, Pharmaceutical Industry 9

  9. Product Life Cycle, Pharmaceutical Industry 10

  10. Advantages and Challenges specific to generic medicines ADVANTAGES RESULTING CHALLENGES Established Product (Up to 20 years history) Proven Equivalence Low Cost Supply Greater availability • Process Chemistry • Costs: • Raw materials • Manufacturing • Control of the Value Chain Life-cycle Management, Outsourcing to non-EU countries, Operationalising Sustainability, Minimising the environmental impact of the business. 11

  11. Actavis EHS OVERVIEW PRESENTATION

  12. Actavis Environmental,Health & Safety (EHS) Policy Actavis is committed to operating all aspects of its business in a safe and responsible manner that protects the environment, and promotes the health & welfare of employees and the communities we operate in. 13

  13. Actavis EHS Commitment- Action Plan • Establish & monitor ambitious objectives and targets to prevent occupational injury, illness or environmental pollution • Proactively manage our EHS risks to ensure compliance with all applicable legal and other requirements • Operate efficiently by integrating EHS considerations into our planning and decision making • Use our flexibility to continuously improve our EHS performance • Openly communicate our goals and performance to all stakeholders, including customers • Work together as a team to promote a positive culture where every employee accepts personal responsibility for EHS 14

  14. Actavis EHS Policy Reflected in Strategic Objectives To fulfil our EHS policy and achieve the vision outlined therein, the following strategic priorities direct our efforts: • Improve the Actavis injury & illness rate, and environmental performance • Reduce EHS risks in all Actavis operations • Achieve 100% compliance • Integrate EHS into the way we do business • Continuously improve EHS performance 15

  15. Continuously improve our incident rate Reduce EHS risks Achieve 100% compliance Implement an independently verifiable EHS management system across all operating sites Continuously improve EHS performance Metrics: Proactive Reactive Focussed strategic initiatives. Independent Certification Training Auditing program Key programs on Energy management & Waste management Strategy implementation Actavis Environmental, Health & Safety (EHS) HOW STRATEGIC OBJECTIVES 16

  16. Actavis EHS - Performance Control Cycle / PDCA loop Set Objectives Take Corrective action Continue Measure Review progress 17

  17. Strategic objectives Policy Strategy Company wide Goals Divisional Goals Facility Goals Actavis EHS - Goal Setting 18

  18. “… Advances in science and technology have brought us tremendous improvements in areas like medicine…For all the advantages we have gained from our new technologies, we have also witnessed many unanticipated side effects.” P.232. “AN INCONVENIENT TRUTH”, Al Gore. 2006 19

  19. Way forward... • The EGA is committed to concrete action: • Providing access to high-quality medicines produced in conditions minimising the environmental footprint and managed through their life-cycle • Support EU sustainability initiatives aimed at fostering Environment, Health and Safety excellence in the pharmaceutical sector 20

  20. Thank you! Sean Bowler Actavis sebowler@actavis.com

More Related